Cargando…

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The LEADER trial demonstrated that the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide reduces kidney and cardiovascular (CV) risk in patients with type 2 diabetes. We previously developed a Parameter Response Efficacy (PRE) score that translates multiple short-term risk marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tye, Sok Cin, de Vries, Sieta T., Mann, Johannes F. E., Schechter, Meir, Mosenzon, Ofri, Denig, Petra, Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044907/ https://www.ncbi.nlm.nih.gov/pubmed/35496307 http://dx.doi.org/10.3389/fphar.2022.786767

Ejemplares similares

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
por: Schechter, Meir, et al.
Publicado: (2020)

Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives
por: Ambrož, Martina, et al.
Publicado: (2021)

Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020
por: Ambrož, Martina, et al.
Publicado: (2022)

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
por: Schechter, Meir, et al.
Publicado: (2022)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients
por: Sokooti, Sara, et al.
Publicado: (2022)

Trends in HbA(1c) thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients
por: Ambrož, Martina, et al.
Publicado: (2020)

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i
por: Blonde, Lawrence, et al.
Publicado: (2021)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty
por: Ambrož, Martina, et al.
Publicado: (2020)

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study
por: de Vries, Sieta T, et al.
Publicado: (2014)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

When drug treatments bias genetic studies: Mediation and interaction
por: Schmidt, Amand F., et al.
Publicado: (2019)

Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care
por: Ambrož, Martina, et al.
Publicado: (2022)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study
por: Kliuk-Ben Bassat, Orit, et al.
Publicado: (2022)

Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study
por: de Vries, Sieta T., et al.
Publicado: (2020)

Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care
por: Denig, Petra, et al.
Publicado: (2019)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Early Insulinization to Prevent Diabetes Progression
por: Raz, Itamar, et al.
Publicado: (2013)

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
por: Garvey, W. Timothy, et al.
Publicado: (2020)

Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington’s Disease
por: Shawki, Samar M., et al.
Publicado: (2021)

Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands
por: de Vries, Esther, et al.
Publicado: (2020)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vkko6mfkd7lg99aogbu7bn4q2q